Eli Lilly Slips After UK Declines to Cover Alzheimer’s Drug

Eli Lilly slips after UK declines to cover Alzheimer’s drug

Analysts polled by FactSet expect the drug, Kisunla, to generate $153.3 million in revenue for Lilly this year....

FDA-Approved Alzheimer’s Drug Lecanemab Found Well-Tolerated in Real-World Use Despite Initial Safety Concerns

A recent evaluation of lecanemab, an Alzheimer’s […] The post FDA-Approved Alzheimer’s Drug Lecanemab Found Well-Tolerated in Real-World Use Despite Initial Safety Concerns first appeared on GeneOnline News. The post FDA-Approved Alzheimer’s Drug Lecanemab Found Well-Tolerated in Real-World Use Despite Initial Safety Concerns appeared first on GeneOnline News.